Matches in Nanopublications for { ?s ?p "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP947103.RAAhQtDs8a3bzf2hjUsnA2lTtpt8qu_cqdt5tM5VVYZic130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP947103.RAAhQtDs8a3bzf2hjUsnA2lTtpt8qu_cqdt5tM5VVYZic130_provenance.
- NP704983.RA8Wnupvx1yy-d4QCGeYT3n7vQqMzG52pVDAp7Kqmn2Js130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP704983.RA8Wnupvx1yy-d4QCGeYT3n7vQqMzG52pVDAp7Kqmn2Js130_provenance.
- NP946982.RAbaeoeXqDMvqjjkztA8SBQSJhsFSCdprjcnGAHFh450k130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP946982.RAbaeoeXqDMvqjjkztA8SBQSJhsFSCdprjcnGAHFh450k130_provenance.
- NP925900.RA14Ews8HI4E4HUvNwpxvRa3HvEVHoj6a4pXe6vrasm40130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925900.RA14Ews8HI4E4HUvNwpxvRa3HvEVHoj6a4pXe6vrasm40130_provenance.
- NP336876.RAwkGkgy6H3Fvpl5fAifNfcTZZGG0JTxELuDEYD06OTzw130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP336876.RAwkGkgy6H3Fvpl5fAifNfcTZZGG0JTxELuDEYD06OTzw130_provenance.
- NP336875.RAXx6sHHM38sawnoocOGfdZ_iE-1lfeUAjT0kA_e67c-I130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP336875.RAXx6sHHM38sawnoocOGfdZ_iE-1lfeUAjT0kA_e67c-I130_provenance.
- NP336874.RAHA5MMUR9JlQJobdH1JWuw7Sp3CBmFGCIALMX0XYAEJY130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP336874.RAHA5MMUR9JlQJobdH1JWuw7Sp3CBmFGCIALMX0XYAEJY130_provenance.
- NP925998.RAHnJI4Stjyqgo8ex4WuUVtQydtzAwx52DpP3UUqSI-2A130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925998.RAHnJI4Stjyqgo8ex4WuUVtQydtzAwx52DpP3UUqSI-2A130_provenance.
- NP336873.RAtRfL9BsWhDAO-UeBi0PvWIdSqUxqP3FDiNqpNDL4-E8130_assertion description "[Paclitaxel and SN-38 (an active metabolite of irinotecan (CPT-11)) are two drugs that are effective in patients with DDP-resistant ovarian cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP336873.RAtRfL9BsWhDAO-UeBi0PvWIdSqUxqP3FDiNqpNDL4-E8130_provenance.